EA200801309A1 - ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ - Google Patents

ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ

Info

Publication number
EA200801309A1
EA200801309A1 EA200801309A EA200801309A EA200801309A1 EA 200801309 A1 EA200801309 A1 EA 200801309A1 EA 200801309 A EA200801309 A EA 200801309A EA 200801309 A EA200801309 A EA 200801309A EA 200801309 A1 EA200801309 A1 EA 200801309A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patients
introduction
treatment
mtor inhibitor
malignant tumor
Prior art date
Application number
EA200801309A
Other languages
English (en)
Other versions
EA015922B1 (ru
Inventor
Кэмилл Л. Бедроужн
Original Assignee
Ариад Джин Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ариад Джин Терапьютикс, Инк. filed Critical Ариад Джин Терапьютикс, Инк.
Publication of EA200801309A1 publication Critical patent/EA200801309A1/ru
Publication of EA015922B1 publication Critical patent/EA015922B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Раскрыты способы лечения пациента ингибитором mTOR, таким как АР23573, сиролимус, темсиролимус, эверолимус и т.д.
EA200801309A 2005-11-14 2006-11-14 ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ EA015922B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73676305P 2005-11-14 2005-11-14
PCT/US2006/044146 WO2007059106A2 (en) 2005-11-14 2006-11-14 Administration of mntor inhibitor to treat patients with cancer

Publications (2)

Publication Number Publication Date
EA200801309A1 true EA200801309A1 (ru) 2008-10-30
EA015922B1 EA015922B1 (ru) 2011-12-30

Family

ID=38049229

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801309A EA015922B1 (ru) 2005-11-14 2006-11-14 ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ

Country Status (9)

Country Link
US (1) US20070185150A1 (ru)
EP (2) EP2662082A1 (ru)
JP (2) JP5709354B2 (ru)
CN (2) CN102579467A (ru)
AU (1) AU2006315512B2 (ru)
CA (1) CA2629714A1 (ru)
EA (1) EA015922B1 (ru)
IL (1) IL191356A0 (ru)
WO (1) WO2007059106A2 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016633A2 (en) * 2006-08-02 2008-02-07 Ariad Gene Therapeutics, Inc. Combination therapy
AU2007319825B2 (en) * 2006-11-14 2014-01-23 Ariad Pharmaceuticals, Inc. Oral formulations
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
JP5719347B2 (ja) 2009-04-16 2015-05-20 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌治療のための組成物及び方法
US8911766B2 (en) * 2009-06-26 2014-12-16 Abbott Cardiovascular Systems Inc. Drug delivery compositions including nanoshells for triggered drug release
US10485792B2 (en) 2009-08-26 2019-11-26 Hadasit Medical Research Services & Development Limited Sustained release delivery systems for the prevention and treatment of head and neck cancers
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
KR101830455B1 (ko) * 2010-04-13 2018-02-20 노파르티스 아게 시클린 의존성 키나제 ４ 또는 시클린 의존성 키나제 （ｃｄｋ４／６） 억제제 및 ｍｔｏｒ 억제제를 포함하는 암 치료를 위한 조합물
JP2012061053A (ja) 2010-09-14 2012-03-29 Yuuki Kitaoka 投薬装置、投薬装置の作動方法及び投薬方法
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
CA2833962A1 (en) * 2011-04-25 2012-11-01 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
WO2013082344A1 (en) * 2011-12-02 2013-06-06 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
SG11201406550QA (en) * 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
US9757432B2 (en) * 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CN106166296A (zh) * 2016-07-01 2016-11-30 江南大学 一种辅助雷帕霉素治疗多种肿瘤的药物组合物
CN107714719A (zh) * 2017-11-08 2018-02-23 上海市第妇婴保健院 雷帕霉素在制备治疗白细胞介素‑27低表达子宫内膜癌的药物中的应用
JP7530116B2 (ja) * 2020-02-21 2024-08-07 コリア アドヴァンスド インスティテュート オブ サイエンス アンド テクノロジー エムトール信号伝達抑制剤を有効成分として含む癌の予防又は治療用薬剤学的組成物
CN114767867A (zh) * 2021-12-22 2022-07-22 中山大学孙逸仙纪念医院 一种用于治疗cdk4/6抑制剂耐药后的乳腺癌的药物组合物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
DE69435044T2 (de) 1993-04-23 2008-09-18 Wyeth Rapamycin - Konjugate und Antikörper
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DK1033128T4 (da) 1993-09-28 2012-03-19 Scherer Gmbh R P Blød gelatinekapselfremstilling
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0000482D0 (en) 2000-01-11 2000-03-01 Norton Healthcare Ltd Enteric coated pharmaceutical formulation
EP2269603B1 (en) 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
IL157898A0 (en) * 2001-04-06 2004-03-28 Wyeth Corp Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
ATE317850T1 (de) 2001-05-30 2006-03-15 Novartis Pharma Gmbh 2-((n-(2-amino-3-(heteroaryl- oder - aryl)propionyl)aminoacyl)amino)- alkylboronsäurederivate
PL216224B1 (pl) 2002-02-01 2014-03-31 Ariad Pharmaceuticals Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
CN100415233C (zh) 2002-09-17 2008-09-03 惠氏公司 口服制剂
BRPI0413745A (pt) * 2003-08-18 2006-10-24 Pfizer Prod Inc horário mde dosagem para agentes anticancerìgenos erbb2
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
ES2298861T3 (es) 2004-01-08 2008-05-16 Wyeth Composicion farmaceutica que puede obtenerse mediante compresion directa para la administracion oral de cci-779.
US7405497B2 (en) 2004-04-13 2008-07-29 Electrovaya Inc. Integrated power supply system
MX2007003790A (es) * 2004-09-30 2007-05-24 Ariad Gene Therapeutics Inc Metodo de tratamiento.
KR20070104908A (ko) * 2005-02-15 2007-10-29 와이어쓰 경구적으로 생체이용가능한 ｃｃｉ-779 정제 제형물
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
DE102005017313A1 (de) 2005-04-14 2006-10-19 Volkswagen Ag Verfahren zur Darstellung von Informationen in einem Verkehrsmittel und Kombiinstrument für ein Kraftfahrzeug
WO2007056117A1 (en) * 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate

Also Published As

Publication number Publication date
EP1962839A4 (en) 2010-08-25
CN101360495B (zh) 2012-03-14
CN101360495A (zh) 2009-02-04
EP2662082A1 (en) 2013-11-13
WO2007059106A3 (en) 2008-06-05
CN102579467A (zh) 2012-07-18
CA2629714A1 (en) 2007-05-24
JP2009515901A (ja) 2009-04-16
EA015922B1 (ru) 2011-12-30
IL191356A0 (en) 2009-08-03
JP5709354B2 (ja) 2015-04-30
JP2014012721A (ja) 2014-01-23
EP1962839A2 (en) 2008-09-03
AU2006315512B2 (en) 2012-11-01
US20070185150A1 (en) 2007-08-09
WO2007059106A2 (en) 2007-05-24
AU2006315512A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
EA200801309A1 (ru) ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
RU2008124827A (ru) Лечение нейроэндокринных опухолей
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
EA201270247A1 (ru) Способы применения с-мет-модуляторов
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EP2298304A3 (en) Carboline derivatives useful in the treatment of cancer
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
EA200700225A1 (ru) Аналоги тетрапептида
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
NZ595572A (en) Inhibitors of pi3 kinase and / or mtor
WO2008077077A3 (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
WO2007050784A3 (en) Fixed ratio drug combination treatments for solid tumors
DE602005024012D1 (de) Lösungsmittelfreies amorphes rapamycin
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
WO2007047608A3 (en) Fibrin targeted therapeutics
NO20064894L (no) Beta-karboliner anvendbare for behandling av inflammatoriske sykdommer
IL200410A0 (en) Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
BRPI0618198A2 (pt) métodos de tratamento, prevenção ou inibição de câncer e de linfoma, composição, kit, e, método de tratamento de câncer resistente a terapia
CY1117438T1 (el) Μεθοδος για την προληψη και την θεραπευτικη αντιμετωπιση της σηψης

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU